Table 4.
Ref. | Year | Targeted patients | Treatment | Predicted outcome | Number of patients | C-index | Validation | Calibration | Variables | Comments |
Jwa et al[37] | 2014 | Non-metastatic rectal cancer | CRT + surgery | ypN status | 891 | 0.77-0.81 | Present | Present | ypT, cN, histology, lymphovascular invasion, perineural invasion, age | |
van Stiphout et al[38] | 2011 | Rectal cancer | CRT + surgery | Pathologic complete response | 953 | Not assessed | Present | Present | tumor length, RI, SUV | Pre- and post-CRT PET-CTs were used to predict response |
van Stiphout et al[39] | 2014 | Rectal cancer | CRT + surgery | Pathologic complete response | 190 | 0.70-0.78 | Present | Absent | Maximal diameter at day 15, RI, cN | Pre- and intra-CRT PET-CTs were used to predict response |
Omata et al[40] | 2011 | Asymptomatic individuals | Colorectal neoplasms | 1085 | Not assessed | Absent | Absent | Quantitative fecal immunochemical test, gender, age, BMI | ||
Kawai et al[41] | 2014 | Colorectal cancer | Surgery | Postoperative development of metachronous colorectal neoplasms | 309 | 0.71 | Present | Present | Gender, age, No. of synchronous adenomas and colorectal cancers | |
Wells et al[42] | 2014 | Age > 45 | Colorectal cancer development | 180630 | 0.68 | Absent | Present | Age, ethnicity, smoking, alcoholic drinks, BMI, education, aspirin, estrogen, family history of CRC, NSAIDs, multivitamins, red meat intake, diabetes, physical activity |
CRT: Chemoradiotherapy; PET-CT: Positron emission tomography-computed tomography; RI: Response index; SUV: Standardized uptake value; CRC: Colorectal cancer; BMI: Body mass index; C-index: Concordance index; NSAID: Non-steroidal anti-inflammatory drug.